C-POST protocol update: A phase 3, randomized, double-blind study of adjuvant cemiplimab versus placebo post-surgery and radiation therapy (RT) in patients (pts) with high-risk cutaneous squamous cell carcinoma (CSCC).

被引：0

作者：

Rischin, Danny

Brungs, Daniel

Day, Fiona

Christie, Hayden Robert

Patel, Vishal A.

Adams, Gerard

Jackson, James Estes

Schurmann, Maite De Liz Vassen

Kirtbaya, Dmitry

Shin, Thuzar M.

Hart, Christopher David

Stankevich, Elizabeth

Li, Siyu

Lowy, Israel

Han, Hyunsil

Fury, Matthew G.

Porceddu, Sandro

机构：

[1] Peter MacCallum Canc Ctr, Dept Med Oncol, Melbourne, Vic, Australia

[2] Wollongong Hosp, Illawarra Canc Care Ctr, Wollongong, NSW, Australia

[3] Calvary Mater Newcastle, Dept Med Oncol, Waratah, Australia

[4] Canc Care Ctr Hervey Bay, Urraween, Australia

[5] George Washington Univ, Inst Patient, Ctr Initiat & Hlth Equ, Sch Med Hlth Sci, Washington, DC USA

[6] Genesis Canc Care, Bundaberg, Qld, Australia

[7] Radiat Oncol Ctr, Gold Coast, Australia

[8] Univ Planalto Catarinense UNIPLAC, Animi Oncol Treatment Unit, Lages, SC, Brazil

[9] State Budgetary Inst, Hlth Oncol Dispensary 2, Krasnodar, Russia

[10] Hosp Univ Penn, Perelman Ctr Adv Med, Dept Dermatol, Philadelphia, PA USA

[11] St Vincents Hosp, Fitzroy, Vic, Australia

[12] Regeneron Pharmaceut Inc, Tarrytown, NY USA

[13] Univ Queensland, Sch Med, Herston, Qld, Australia

来源：

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

TPS9592

引用

页数：1